Le Lézard
Classified in: Business
Subject: ATY

INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Altimmune Inc. to Contact Law Firm


NEW YORK, May 9, 2024 /PRNewswire/ -- Moore Law, PLLC, a securities and shareholder law firm located on Wall Street, is investigating potential claims against:

*please contact [email protected] 

The investigation concerns allegations of false and/or misleading statements, as well as a failure to disclose material facts, that: (i) Altimmune overstated the potential for pemvidutide to stand out from competing GLP-1 agonists based on the drug's efficacy and tolerability results observed in the MOMENTUM Trial; (ii) accordingly, the MOMENTUM Trial results were less significant to pemvidutide's clinical, commercial, and competitive prospects than investors were led to believe; and (iii) as a result of all the foregoing, defendants had overstated Altimmune's prospects for finding a strategic partner to develop pemvidutide.

On February 13, 2024, Kerrisdale Capital published a report alleging that "a deeper examination of Altimmune's data reveals a drug with little chance of competing against either the approved incumbents or the other GLP-1 agonists progressing through clinical trials." On this news, Altimmune's stock price fell $1.94 per share, or 18.65%, to close at $8.46 per share on February 13, 2024.

Then, on April 29, 2024, Bloomberg published an article entitled "Altimmune Down as Guggenheim Sees Overhang in No Partnership," reporting that "Guggenheim Securities downgraded [Altimmune's] stock to neutral from buy saying [a] partnership for the biotech's lead asset pemvidutide look[s] 'increasingly unlikely.'" On this news, Altimmune's stock price fell $0.87 per share, or 11.98%, to close at $6.39 per share on April 29, 2024.

There is no cost to you. We will never send you a bill or ask for payment. Attorney advertising.

ABOUT MOORE LAW PLLC

Moore Law is a litigation law firm for investors seeking to enforce their rights. We hold officers and directors accountable for breaches of fiduciary duty, fraud, insider trading, wasteful spending, and other corporate malfeasance. We strengthen corporate governance reforms to better protect your investments.

Fletcher Moore, Esq.
Moore Law, PLLC
[email protected] 
(212) 709-8245
www.fmoorelaw.com

SOURCE Moore Law PLLC


These press releases may also interest you

at 09:15
Jabil Inc. today announced it is confirming its previously provided third quarter of fiscal year 2024 guidance for net revenue of $6.2 billion to $6.8 billion, U.S. GAAP operating income of $221 million to $301 million, U.S. GAAP diluted earnings...

at 09:10
PermitUsNow, a leading permitting firm recognized for transforming building permitting processes across Houston, is ready to assist commercial and residential property owners with essential permitting guidance following the recent severe weather. The...

at 09:05
Domo today announced that results for its first quarter fiscal 2025 (ended April 30, 2024) will be released on Thursday, May 23, 2024, after the close of the market. The company will host a conference call at 3:00 p.m. (MT) / 5:00 p.m. (ET) to...

at 09:05
PVH Corp. today announced that it will release its first quarter 2024 earnings results on Tuesday, June 4, 2024, after the market closes. PVH will sponsor a conference call on Wednesday, June 5, 2024, beginning at 9:00 A.M. Eastern Time, hosted by...

at 09:05
The Pennsylvania median home sales price reached an all-time high last month, according to a report prepared for the Pennsylvania Association of Realtors®. The median home sales price vaulted to $280,000 in April, up nearly 25% from March and up 7.6%...

at 09:01
MET-Rx, the number one meal replacement brand in sports nutrition, today announced a new multi-year partnership with WWE legend, A-list actor, and philanthropist John Cena. Cena, whose extreme dedication to fitness and nutrition has rocketed him from...



News published on and distributed by: